Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking Endocrine Therapy, VENT Trial

NCT06617455 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

9

Enrollment

OTHER

Sponsor class

Stopped Lack of Patient Interest

Conditions

Anatomic Stage I Breast Cancer AJCC v8
Anatomic Stage II Breast Cancer AJCC v8
Anatomic Stage III Breast Cancer AJCC v8
Breast Ductal Carcinoma In Situ
Localized Breast Carcinoma

Interventions

PROCEDURE: Biospecimen Collection
DRUG: Fezolinetant
DRUG: Placebo Administration
OTHER: Quality-of-Life Assessment
OTHER: Questionnaire Administration

Sponsor

University of Michigan Rogel Cancer Center

Collaborators

[object Object]